3 days popular7 days popular1 month popular3 months popular

Korean scientists publish the latest results on colorectal cancer screening using the M2-PK test

Scientists from the College of Medicine at the Catholic University of Korea have published newest data on the M2-PK test from a multi-center study of in the journal Gut and Liver. The results from cancer expert Professor Yong Kim and his colleagues confirm the exceptionally high capability of the M2-PK test, particularly in comparison to the immunological (iFOBT), to detect adenomas and .

In their study Professor Kim and colleagues investigated the enzymatic biomarker M2-PK with volunteers in patient groups with 139 cases of colorectal cancer and 124 with adenoma, along with a population-based control group of 60 people, making a total of 323 subjects. The sensitivity of the M2-PK test was 92.8% for colorectal cancer and 69.4% for adenomas. In addition, they also compared the results of the M2-PK test with those of an immunological fecal occult blood test (iFOBT). This was clearly inferior to the M2-PK test. The iFOBT detected only 47.5% of the colon cancers and just 12.1% of the adenomas. Consequently, the M2-PK test detected twice as many colorectal cancer cases and nearly six times the number of adenomas than the immunological fecal occult blood test (iFOBT). These scientific results from the University of Korea categorically confirm the capability of the fecal M2-PK test for screening and early detection of colorectal cancer.

The fecal M2-PK test is available as a qualitative rapid test under the name ScheBo(R) M2-PK Quick(TM) and as a fully quantitative ELISA stool test.

Source

The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test, Yong Cheol Kim, Jeong Ho Kim, Dae Young Cheung, Tae Ho Kim, Eun Jung Jun, Jung-Whan Oh, Chang Whan Kim, Woo Chul Chung, Byung-Wook Kim, Sung Soo Kim, Jin Il Kim, Soo-Heon Park, and Jae Kwang Kim, Gut and Liver, published online 5 December 2014.

Source: ScheBo Biotech AG